On January 4, 2024 FibroBiologics, Inc., a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, reported that it will attend the Biotech Showcase in San Francisco, CA from January 8-10, 2024 (Press release, FibroBiologics, JAN 4, 2024, View Source [SID1234638970]). Biotech Showcase is a premier event for private and mid-cap biotechnology companies to highlight their innovation by connecting with global investors and engaging with executives from prominent biopharmaceutical interests.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FibroBiologics will be represented by Chairman, Founder, and Chief Executive Officer Pete O’Heeron and Chief Scientific Officer Hamid Khoja, Ph.D., who will be presenting on FibroBiologics’ recent corporate milestones and research advances using fibroblasts in indications as diverse as multiple sclerosis, degenerative disc disease, and wound healing.

Details of the event are as follows:
Event: Biotech Showcase 2024
Date: January 9, 2024, at 11:30 a.m. Pacific Standard Time
Location: Hilton San Francisco – Union Square, San Francisco, CA
Track: Yosemite C (Ballroom Level)

"We believe fibroblast-based therapies have been overlooked as a compelling alternative to stem cells and anticipate our presentation at Biotech Showcase will be an opportunity to connect with fellow experts in the field, sharing our latest discoveries about our innovative therapies and initiating dialogue within the community," said Mr. O’Heeron.